Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

18
KLCI remains in the red in slow start to 2H2018

2018-07-02 theedgemarkets
KUALA LUMPUR (July 2): The FBM KLCI remained subdued at mid-morning today after data showed business conditions across Malaysia’s manufacturing sector deteriorating albeit at a slower pace in June.
7052 PBLOF BATS 4162 1295 3794 2089 7077 5199 DKSHY KLKBY 3867 7206 HIPEF 5908 SPMXF UPBMF 8133 1481 5139 2445 4588 SPMXY 0026 0900 5819 DKSHF

58
Consolidation of the oil and gas sector not fast enough

2018-06-12 thestar.com.my
The steady recovery in crude oil prices over the past one year has yet to have a big positive impact on OGSE players. This is partly because oil majors have yet to increase their capex in a big way.
RDS.B RDS.A XOM RDSB RDSA 8133 5255 9466 BHI 7206 5703 RYDBF RYDAF BSMAF 1818

2
BHIC net profit 67% higher to RM4.5mil

2018-05-17 thestar.com.my
PETALING JAYA: Boustead Heavy Industries Corp Bhd (BHIC) recorded a 67% jump in net profit to RM4.5mil for its first quarter ended March 31, 2018 (1Q18), compared with RM2.7mil in the corresponding quarter last year.
8133

2
DSA 2018: Malaysia’s Boustead lines up second batch of Kedah-class vessels

2018-04-19 janes
Malaysia’s Boustead Heavy Industries Corporation (BHIC) is preparing a proposal to supply the Royal Malaysian Navy (RMN) with a second batch of MEKO 100 Kedah-class corvettes, the company has confirmed to Jane’s .
8133

2
DSA 2018: Malaysia’s Boustead leverages Chinese know-how in LMS programme

2018-04-16 janes
Malaysia’s Boustead Heavy Industries Corporation (BHIC) is preparing the second phase of its programme to build littoral mission ships (LMS) for the Royal Malaysian Navy (RMN).
8133

2
BHIC to gain from Navy plan

2018-04-11 thestar.com.my
KUALA LUMPUR: Boustead Heavy Industries Corp Bhd (BHIC) is looking to capitalise on the Royal Malaysian Navy’s (RMN) 30-year transformation programme and is confident of securing an additional RM1bil worth of contracts this year.
8133

2
Boustead Heavy secures RM6b in orders this year

2018-04-11 themalaymailonline
Boustead Heavy Industries Corporation Chairman Tan Sri Datuk Seri Lodin Wok Kamaruddin (right) and director, Tan Sri Datuk Seri Ahmad Ramli Mohd Nor speak during the press conference after their 2017 AGM. — Picture by Mukhriz HazimKUALA LUMPUR, April 11 — Boustead Heavy Industries Corp Bhd (BHIC) announced today it has secured a RM6 billion order book this year for its shipbuilding maintenance, repair and overhaul portfolio.
8133

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...